Display options
Cite
Gulla A, Morelli E, Samur MK, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021;2(5):468-483doi: 10.1158/2643-3230.bcd-21-0047.
Gulla, A., Morelli, E., Samur, M. K., Botta, C., Hideshima, T., Bianchi, G., Fulciniti, M., Malvestiti, S., Prabhala, R. H., Talluri, S., Wen, K., Tai, Y. T., Richardson, P. G., Chauhan, D., Sewastianik, T., Carrasco, R. D., Munshi, N. C., & Anderson, K. C. (2021). Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood cancer discovery, 2(5), 468-483. https://doi.org/10.1158/2643-3230.bcd-21-0047
Gulla, Annamaria, et al. "Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation." Blood cancer discovery vol. 2,5 (2021): 468-483. doi: https://doi.org/10.1158/2643-3230.bcd-21-0047
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.bcd-21-0047. Epub 2021 Apr 23. PMID: 34568832; PMCID: PMC8462183.
Copy Download .nbib Format: NLM
Share it on

Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.bcd-21-0047. Epub 2021 Apr 23.

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.

Blood cancer discovery

Annamaria Gulla, Eugenio Morelli, Mehmet K Samur, Cirino Botta, Teru Hideshima, Giada Bianchi, Mariateresa Fulciniti, Stefano Malvestiti, Rao H Prabhala, Srikanth Talluri, Kenneth Wen, Yu-Tzu Tai, Paul G Richardson, Dharminder Chauhan, Tomasz Sewastianik, Ruben D Carrasco, Nikhil C Munshi, Kenneth C Anderson

Affiliations

  1. Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  2. Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA.
  3. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
  4. Department of Oncohematology, "Annunziata" Hospital, Cosenza, Italy.
  5. Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard medical School, Boston, MA.
  6. Freiburg University Hospital, Department of Pediatric hematology and Oncology, Germany.
  7. VA Boston Healthcare System, Boston, MA.
  8. Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  9. Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  10. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

PMID: 34568832 PMCID: PMC8462183 DOI: 10.1158/2643-3230.bcd-21-0047

Abstract

Proteasome inhibitor bortezomib induces apoptosis in multiple myeloma (MM) cells, and has transformed patient outcome. Using

Keywords: STING; bortezomib; immunogenic cell death (ICD); immunotherapy; multiple myeloma

Conflict of interest statement

Conflict of interest KCA serves on advisory boards to Janssen, Pfizer, Astrazeneca, Amgen, Precision Biosciences, Mana, Starton, and Raqia, and is a Scientific Founder of OncoPep and C4 Therapeutics.

References

  1. N Engl J Med. 2005 Jun 16;352(24):2487-98 - PubMed
  2. N Engl J Med. 2017 Apr 6;376(14):1311-1320 - PubMed
  3. Blood. 2009 Mar 26;113(13):3040-9 - PubMed
  4. Nat Med. 2014 Nov;20(11):1301-9 - PubMed
  5. Nat Rev Clin Oncol. 2020 Dec;17(12):725-741 - PubMed
  6. Cell Rep. 2015 May 19;11(7):1018-30 - PubMed
  7. Best Pract Res Clin Haematol. 2020 Mar;33(1):101143 - PubMed
  8. Nat Med. 2007 Jan;13(1):54-61 - PubMed
  9. J Immunother Cancer. 2020 Mar;8(1): - PubMed
  10. Cancer Metastasis Rev. 2017 Dec;36(4):561-584 - PubMed
  11. Oncoimmunology. 2017 Jan 10;6(4):e1278332 - PubMed
  12. Bioinformatics. 2009 Apr 15;25(8):1091-3 - PubMed
  13. Immunol Rev. 2019 Jul;290(1):24-38 - PubMed
  14. Sci Rep. 2018 Oct 9;8(1):15030 - PubMed
  15. Blood. 2007 Nov 15;110(10):3557-60 - PubMed
  16. Blood. 2020 Dec 10;136(24):2731-2740 - PubMed
  17. J Clin Oncol. 2010 Oct 20;28(30):4630-4 - PubMed
  18. Blood. 2007 Jun 1;109(11):4839-45 - PubMed
  19. Haematologica. 2020 Jul 23;105(10):2358-2367 - PubMed
  20. Biomed Res Int. 2015;2015:172458 - PubMed
  21. BMC Bioinformatics. 2018 Apr 12;19(1):135 - PubMed
  22. Bioinformatics. 2013 Mar 1;29(5):661-3 - PubMed
  23. Leukemia. 2018 Dec;32(12):2626-2635 - PubMed
  24. Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6 - PubMed
  25. Nat Rev Mol Cell Biol. 2020 Sep;21(9):501-521 - PubMed
  26. J Clin Invest. 2016 Jul 1;126(7):2404-11 - PubMed
  27. Front Cell Dev Biol. 2019 Apr 16;7:50 - PubMed
  28. Nat Rev Dis Primers. 2017 Jul 20;3:17046 - PubMed
  29. Nature. 2017 Aug 24;548(7668):461-465 - PubMed
  30. Annu Rev Immunol. 2013;31:51-72 - PubMed
  31. Mol Cell. 2020 Oct 1;80(1):21-28 - PubMed
  32. Nat Rev Immunol. 2015 Jul;15(7):405-14 - PubMed
  33. Leukemia. 2018 Apr;32(4):996-1002 - PubMed
  34. Blood. 2011 Dec 8;118(24):6368-79 - PubMed
  35. Oncoimmunology. 2018 Jul 23;7(10):e1484981 - PubMed
  36. Immunity. 2017 Oct 17;47(4):616-617 - PubMed
  37. Immunol Rev. 2017 Nov;280(1):165-174 - PubMed
  38. Exp Hematol Oncol. 2017 Jul 14;6:20 - PubMed
  39. Cancer Cell. 2015 Dec 14;28(6):690-714 - PubMed
  40. J Exp Med. 2005 Dec 19;202(12):1691-701 - PubMed
  41. Oncoimmunology. 2019 Jul 22;8(10):e1637188 - PubMed
  42. Blood. 2007 Apr 15;109(8):3177-88 - PubMed
  43. Nat Med. 2016 Dec;22(12):1411-1420 - PubMed
  44. Oncoimmunology. 2015 Jul 25;4(8):e988042 - PubMed
  45. Blood. 2020 Jul 9;136(2):199-209 - PubMed
  46. Nature. 2015 Jun 11;522(7555):179-84 - PubMed
  47. Cell Rep. 2019 Oct 15;29(3):785-789 - PubMed
  48. N Engl J Med. 2016 Sep 1;375(9):819-29 - PubMed
  49. Cancer Lett. 2016 Nov 1;382(1):1-10 - PubMed
  50. J Clin Invest. 2008 Jun;118(6):1991-2001 - PubMed

Publication Types

Grant support